Roquette completes the acquisition of IFF Pharma Solutions

Roquette has announced the complete acquisition of IFF Pharma Solutions. This follows that of Qualicaps in 2023, and further strengthens the company’s position in the healthy industry by IFF’s expertise and product portfolio.

The transaction also enhances Roquette’s ability to provide high-value drug delivery solutions to pharmaceutical customers worldwide, and provide cutting-edge solutions that meet evolving industry needs. It supports the company’s long-term strategy of investing in high-growth markets.

Pierre Courduroux, CEO of Roquette, commented: “The successful acquisition of IFF Pharma Solutions marks a major step forward in our value-creation journey. We are thrilled to officially welcome our new colleagues as we start to write the next chapter of Roquette's history. This pivotal move aligns perfectly with our strategic vision to provide innovative, high-quality excipients that improve the efficacy and safety of pharmaceutical formulations. By combining our strengths, Roquette is poised to become the pharmaceutical industry’s go-to partner for the development of drug delivery solutions that contribute to improving, sustaining, and saving patients’ lives.”

Roquette is a family-owned global leader in plant-based ingredients and a leading provider of pharmaceutical excipients. Founded in 1933, the company currently operates in more than 150 countries, through more than 40 manufacturing sites, with a turnover of €4.5 billion in 2024, and employs more than 11,000 people worldwide.